How Much Does Zepbound Cost in Wyoming in 2026?

Wyoming Retail Pricing for Zepbound

The average cash-pay price for brand-name Zepbound at Wyoming retail pharmacies sits at $1,059 per month in 2026, matching Eli Lilly's wholesale acquisition cost. That figure applies across all four maintenance dose strengths (5 mg, 10 mg, 12.5 mg, and 15 mg), since Lilly prices each single-dose pen carton identically.

Wyoming's small population (roughly 577,000 residents) means fewer competing pharmacies than in neighboring Colorado or Utah. Price variation between Casper, Cheyenne, and smaller towns is minimal because most retailers anchor to the same WAC. A few independent pharmacies may offer modest discounts for cash-pay customers, but savings rarely exceed 3% to 5% off list price without a coupon or discount program.

Patients filling at chain pharmacies like Walmart, Walgreens, or CVS will typically see the same $1,059 sticker price. GoodRx and similar aggregator coupons can sometimes shave $50 to $100 off, though availability fluctuates. The real price breaks come from manufacturer programs or compounded alternatives, both discussed below.

Compounded Tirzepatide in Wyoming: Legal Status and Cost

Compounded tirzepatide is legally available in Wyoming through state-licensed 503A compounding pharmacies, with monthly costs averaging $249. That represents a 76% reduction compared to brand-name Zepbound.

Under federal law, 503A pharmacies compound medications pursuant to individual patient prescriptions. Wyoming's Board of Pharmacy permits resident and nonresident 503A pharmacies to dispense compounded tirzepatide as long as they hold valid state licensure and comply with USP <797> sterility standards. The FDA has kept tirzepatide off its "difficult to compound" list as of early 2026, which means 503A pharmacies can continue producing it.

A critical distinction: compounded tirzepatide is not FDA-approved Zepbound. The active ingredient is the same molecule, but compounded versions lack the brand product's specific device, formulation testing, and regulatory review pathway. The FDA's guidance on compounding notes that compounded drugs "are not FDA-approved" and do not undergo the same premarket review.

Patients choosing compounded tirzepatide should verify that their pharmacy holds both a Wyoming nonresident (or resident) pharmacy license and compounds under current USP <797> standards. Ask the pharmacy for a certificate of analysis (COA) for each batch. Pricing at Wyoming-serving 503A pharmacies ranges from $199 to $349 per month depending on dose strength, with 5 mg vials at the lower end and 15 mg at the upper end.

Wyoming Medicaid and Zepbound Coverage

Wyoming Medicaid does not cover Zepbound for chronic weight management as of 2026. This mirrors the majority of state Medicaid programs, which classify GLP-1/GIP receptor agonists for obesity as non-preferred or excluded.

Wyoming's Medicaid preferred drug list (PDL) includes tirzepatide under its brand name Mounjaro for type 2 diabetes, subject to prior authorization demonstrating a diagnosis of T2DM and failure of metformin monotherapy. The weight-management indication, which the FDA approved under the Zepbound brand in November 2023, falls outside this coverage. Wyoming's Department of Health has not announced plans to add anti-obesity medications to the PDL for the 2026-2027 fiscal year.

For Wyoming Medicaid enrollees with type 2 diabetes and concurrent obesity, there may be a pathway: if a prescriber documents the primary indication as T2DM, Mounjaro (same molecule, different brand) could be authorized. The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends tirzepatide as a first-line pharmacotherapy option for adults with BMI ≥30 kg/m², and some prior authorization appeals cite this guideline. Success rates on appeal vary.

Roughly 53,000 Wyoming adults are enrolled in Medicaid. For those who do not qualify through the diabetes pathway, the compounded tirzepatide route or the Lilly savings card (if they obtain commercial insurance) remain the primary affordable options.

Private Insurance Coverage in Wyoming

Commercial insurers in Wyoming vary widely on Zepbound coverage. The state's individual and small-group market is dominated by Blue Cross Blue Shield of Wyoming and Cigna. Large employers often self-insure through national carriers.

Blue Cross Blue Shield of Wyoming listed Zepbound as non-preferred but accessible through prior authorization on select 2026 plans. Criteria typically require documentation of BMI ≥30 (or ≥27 with hypertension, dyslipidemia, or obstructive sleep apnea), a 90-day trial of lifestyle modification, and failure of at least one prior weight-management medication.

Self-insured employer plans, which cover a significant share of Wyoming's working population, set their own formulary rules. Employees should request a formulary exception or step-therapy override if Zepbound is excluded. The American Association of Clinical Endocrinology (AACE) consensus statement on obesity pharmacotherapy supports tirzepatide as appropriate when first-line agents are insufficient, which can strengthen appeals.

One data point worth noting: in SURMOUNT-1 (N=2,539), participants on tirzepatide 15 mg achieved 22.5% mean body weight reduction at 72 weeks, compared with 3.1% for placebo. That magnitude of weight loss often crosses the threshold insurers use to justify coverage, particularly when linked to improvement in cardiometabolic risk markers. A secondary analysis of SURMOUNT-1 showed that 63% of participants on the 15 mg dose achieved ≥20% weight loss [1].

The Eli Lilly Zepbound Savings Card

Eli Lilly offers a savings card program that can reduce out-of-pocket Zepbound costs to $25 per month for eligible patients with commercial insurance. The card is also available to cash-pay patients at a reduced, though higher, rate.

Eligibility requirements: the patient must have a valid Zepbound prescription, be a U.S. resident, and carry commercial (non-government) insurance. Patients on Medicare, Medicaid, TRICARE, or other federal/state programs are excluded. Wyoming residents with employer-sponsored or ACA marketplace plans through BCBS of Wyoming or Cigna are generally eligible.

For commercially insured patients whose plan covers Zepbound (even with a high copay), the savings card covers the difference between the patient's copay and $25, up to a maximum monthly benefit. For cash-pay patients without insurance coverage, Lilly introduced a direct-pay option in 2024 offering single-dose vials at lower price points, though availability has shifted over time. Check Lilly's Zepbound cost information page or call the Lilly support line at 1-800-545-6962 for current program terms.

Dr. Robert Kushner, a professor of medicine at Northwestern University and principal investigator on multiple obesity pharmacotherapy trials, has stated: "The biggest barrier to GLP-1 receptor agonist therapy is not efficacy. It's access. Manufacturer savings programs are filling a gap that insurance hasn't closed."

Telehealth Access to Zepbound in Wyoming

Wyoming permits telehealth prescribing of Zepbound statewide, and the state's vast geography makes telemedicine a practical default for many residents. Wyoming law allows synchronous audio-video telehealth visits to establish a prescriber-patient relationship, which satisfies the requirements for prescribing a Schedule-unscheduled prescription medication like tirzepatide.

National telehealth platforms (Ro, Hims, Found, Calibrate, and HealthRX) serve Wyoming ZIP codes and can prescribe brand-name Zepbound or, in some cases, coordinate compounded tirzepatide from a licensed 503A pharmacy. Visit costs range from $0 (bundled into subscription programs) to $149 for an initial consultation.

For patients in rural Wyoming counties, where the nearest endocrinologist or obesity medicine specialist may be 100+ miles away, telehealth removes a real geographic barrier. The CDC's data on obesity prevalence shows Wyoming's adult obesity rate at approximately 29%, meaning a substantial portion of the population may benefit from pharmacotherapy access.

A practical note: Wyoming does not require an in-person visit before a telehealth prescriber can write a Zepbound prescription, but some insurers may require documentation of an established care relationship. Patients should confirm their specific plan's telehealth reimbursement policies before scheduling.

Clinical Evidence Behind Zepbound

Tirzepatide is a dual GIP/GLP-1 receptor agonist. It works on two incretin pathways simultaneously, which distinguishes it from semaglutide (Wegovy/Ozempic), a GLP-1-only agonist.

The key SURMOUNT-1 trial enrolled 2,539 adults with BMI ≥30 (or ≥27 with at least one weight-related comorbidity) and no diabetes. At 72 weeks, tirzepatide produced dose-dependent weight loss: 15.0% (5 mg), 19.5% (10 mg), and 22.5% (15 mg) versus 3.1% for placebo [1]. These results exceeded what semaglutide 2.4 mg achieved in the STEP-1 trial (N=1,961), which reported 14.9% mean weight loss at 68 weeks [2].

SURMOUNT-2 studied tirzepatide specifically in adults with type 2 diabetes and obesity (N=938). Participants on the 15 mg dose lost 14.7% of body weight at 72 weeks versus 3.2% on placebo, with HbA1c reductions of 2.1 percentage points [3]. This dual benefit is why some Wyoming prescribers initiate tirzepatide under the Mounjaro (diabetes) label when patients have both conditions.

The most common adverse events across SURMOUNT trials were gastrointestinal: nausea (24-33%), diarrhea (18-25%), and constipation (11-17%). These were predominantly mild to moderate and decreased over time. Serious adverse events occurred at similar rates in treatment and placebo arms. The FDA prescribing information includes a boxed warning regarding thyroid C-cell tumors observed in rodent studies, though this has not been confirmed in humans [4].

Dr. Ania Jastreboff, associate professor at Yale School of Medicine and lead author of SURMOUNT-1, noted at the 2023 ADA Scientific Sessions: "The degree of weight reduction with tirzepatide approaches what we previously only saw with bariatric surgery, but through a once-weekly injection."

How to Minimize Zepbound Costs in Wyoming: A Decision Framework

The right cost-reduction strategy depends on your insurance status.

Commercially insured (BCBS of Wyoming, Cigna, employer plan): Apply for the Eli Lilly savings card first. If your plan covers Zepbound even partially, you may pay $25 per month. If your plan excludes it, file a formulary exception citing SURMOUNT-1 data and AACE guidelines. Allow 2-4 weeks for the appeal process.

Uninsured or cash-pay: Compounded tirzepatide from a licensed 503A pharmacy is the most cost-effective route at roughly $249 per month. Verify the pharmacy's Wyoming license and request a COA. Some telehealth platforms bundle the prescription visit fee into the compounded medication cost.

Wyoming Medicaid: Brand Zepbound is not covered for weight management. If you have concurrent type 2 diabetes, your prescriber may be able to pursue prior authorization for Mounjaro (same molecule). Without a diabetes diagnosis, compounded tirzepatide is the primary affordable option.

Medicare (Part D): Medicare does not cover anti-obesity medications. The Lilly savings card is also excluded for Medicare beneficiaries. Compounded tirzepatide remains the fallback, though some Medicare Advantage plans have begun pilot coverage programs in select states. Wyoming is not among them as of May 2026.

Patients should dose-titrate per the FDA label (start at 2.5 mg weekly for 4 weeks, then increase to 5 mg) regardless of the source. Skipping the titration schedule to save money by using fewer pens increases nausea risk and does not improve long-term outcomes [4].